Mitochondrial Causes of Epilepsy: Evaluation, Diagnosis, and Treatment

Hannah E. Steele; Patrick F. Chinnery

doi:10.1055/s-0035-1552624

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2015; 35(03): 300-309
DOI: 10.1055/s-0035-1552624

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mitochondrial Causes of Epilepsy: Evaluation, Diagnosis, and Treatment

Authors

Hannah E. Steele

¹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

²Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
Patrick F. Chinnery

¹Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

²Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

Abstract

Mitochondrial disorders are frequently associated with seizures. In this review, the authors discuss the seizure patterns and distinguishing features of mitochondrial epilepsy, alongside the indications for investigating, and how to investigate epilepsy from a mitochondrial perspective. Finally, they discuss management strategies for this complex group of patients.

Keywords

epilepsy - mitochondrial disease - investigation - diagnosis - treatment

Volltext

Referenzen

References
1 Nesbitt V, Pitceathly RD, Turnbull DM , et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation—implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013; 84 (8) 936-938
2 Chevallier JA, Von Allmen GK, Koenig MK. Seizure semiology and EEG findings in mitochondrial diseases. Epilepsia 2014; 55 (5) 707-712
3 Canafoglia L, Franceschetti S, Antozzi C , et al. Epileptic phenotypes associated with mitochondrial disorders. Neurology 2001; 56 (10) 1340-1346
4 Demarest ST, Whitehead MT, Turnacioglu S, Pearl PL, Gropman AL. Phenotypic analysis of epilepsy in the mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes-associated mitochondrial DNA A3243G mutation. J Child Neurol 2014; 29 (9) 1249-1256
5 Lorenzoni PJ, Scola RH, Kay CS, Arndt RC, Silvado CE, Werneck LC. MERRF: Clinical features, muscle biopsy and molecular genetics in Brazilian patients. Mitochondrion 2011; 11 (3) 528-532
6 Mancuso M, Orsucci D, Angelini C , et al. Phenotypic heterogeneity of the 8344A>G mtDNA “MERRF” mutation. Neurology 2013; 80 (22) 2049-2054
7 Sofou K, De Coo IF, Isohanni P , et al. A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet J Rare Dis 2014; 9: 52
8 El Sabbagh S, Lebre AS, Bahi-Buisson N , et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010; 51 (7) 1225-1235
9 Finsterer J, Zarrouk Mahjoub S. Mitochondrial epilepsy in pediatric and adult patients. Acta Neurol Scand 2013; 128 (3) 141-152
10 Kang HC, Kwon JW, Lee YM, Kim HD, Lee HJ, Hahn SH. Nonspecific mitochondrial disease with epilepsy in children: diagnostic approaches and epileptic phenotypes. Childs Nerv Syst 2007; 23 (11) 1301-1307
11 Lee HF, Chi CS, Tsai CR, Chen CH. Epileptic seizures in infants and children with mitochondrial diseases. Pediatr Neurol 2011; 45 (3) 169-174
12 Lee YM, Kang HC, Lee JS , et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008; 49 (4) 685-690
13 Berg AT, Berkovic SF, Brodie MJ , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51 (4) 676-685
14 Farwell KD, Shahmirzadi L, El-Khechen D , et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med 2014; ; e-pub ahead of print
15 Taylor RW, Pyle A, Griffin H , et al. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. JAMA 2014; 312 (1) 68-77
16 Schaefer AM, McFarland R, Blakely EL , et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63 (1) 35-39
17 Han JY, Sung JJ, Park HK, Yoon BN, Lee KW. Adult onset Leigh syndrome with mitochondrial DNA 8344 A>G mutation. J Clin Neurosci 2014; 21 (11) 2009-2011
18 McKelvie P, Infeld B, Marotta R, Chin J, Thorburn D, Collins S. Late-adult onset Leigh syndrome. J Clin Neurosci 2012; 19 (2) 195-202
19 Rahman S, Blok RB, Dahl HH , et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39 (3) 343-351
20 Lee HF, Tsai CR, Chi CS, Lee HJ, Chen CC. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009; 40 (2) 88-93
21 Naess K, Freyer C, Bruhn H , et al. MtDNA mutations are a common cause of severe disease phenotypes in children with Leigh syndrome. Biochim Biophys Acta 2009; 1787 (5) 484-490
22 Arii J, Tanabe Y. Leigh syndrome: serial MR imaging and clinical follow-up. AJNR Am J Neuroradiol 2000; 21 (8) 1502-1509
23 Ruhoy IS, Saneto RP. The genetics of Leigh syndrome and its implications for clinical practice and risk management. Appl Clin Genet 2014; 7: 221-234
24 Saneto RP, Cohen BH, Copeland WC, Naviaux RK. Alpers-Huttenlocher syndrome. Pediatr Neurol 2013; 48 (3) 167-178
25 Hunter MF, Peters H, Salemi R, Thorburn D, Mackay MT. Alpers syndrome with mutations in POLG: clinical and investigative features. Pediatr Neurol 2011; 45 (5) 311-318
26 McCoy B, Owens C, Howley R , et al. Partial status epilepticus - rapid genetic diagnosis of Alpers' disease. Eur J Paediatr Neurol 2011; 15 (6) 558-562
27 Wolf NI, Rahman S, Schmitt B , et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009; 50 (6) 1596-1607
28 Saneto RP, Lee IC, Koenig MK , et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010; 19 (3) 140-146
29 Lupashko S, Malik S, Donahue D, Hernandez A, Perry MS. Palliative functional hemispherectomy for treatment of refractory status epilepticus associated with Alpers' disease. Childs Nerv Syst 2011; 27 (8) 1321-1323
30 Tanji K, Kaufmann P, Naini AB , et al. A novel tRNA(Val) mitochondrial DNA mutation causing MELAS. J Neurol Sci 2008; 270 (1-2) 23-27
31 Tzoulis C, Bindoff LA. Melas associated with mutations in the polg1 gene. Neurology 2008; 70 (13) 1054 , author reply 1054–1055
32 Deschauer M, Tennant S, Rokicka A , et al. MELAS associated with mutations in the POLG1 gene. Neurology 2007; 68 (20) 1741-1742
33 Karkare S, Merchant S, Solomon G, Engel M, Kosofsky B. MELAS with A3243G mutation presenting with occipital status epilepticus. J Child Neurol 2009; 24 (12) 1564-1567
34 Silvestri G, Moraes CT, Shanske S, Oh SJ, DiMauro S. A new mtDNA mutation in the tRNA(Lys) gene associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1992; 51 (6) 1213-1217
35 Van Goethem G, Mercelis R, Löfgren A , et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology 2003; 61 (12) 1811-1813
36 Romaniuk L, Turnbull DM, Whittaker RG. Hyperventilation during the EEG is safe in mitochondrial disease. Clin Neurophysiol 2011; 122 (6) 1270-1271
37 OMIM 174763: Polymerase, DNA, Gamma; POLG. 25/10/2013 ed. Online Mendelian Inheritance in Man; 2013
38 Tang S, Wang J, Lee NC , et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011; 48 (10) 669-681
39 Tzoulis C, Engelsen BA, Telstad W , et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006; 129 (Pt 7) 1685-1692
40 Horvath R, Hudson G, Ferrari G , et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006; 129 (Pt 7) 1674-1684
41 Hakonen AH, Davidzon G, Salemi R , et al. Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. Eur J Hum Genet 2007; 15 (7) 779-783
42 Engelsen BA, Tzoulis C, Karlsen B , et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008; 131 (Pt 3) 818-828
43 Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003; 61 (9) 1238-1244
44 Lönnqvist T, Paetau A, Valanne L, Pihko H. Recessive twinkle mutations cause severe epileptic encephalopathy. Brain 2009; 132 (Pt 6) 1553-1562
45 Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75 (10) 1376-1381
46 Keränen T, Kuusisto H. NARP syndrome and adult-onset generalised seizures. Epileptic Disord 2006; 8 (3) 200-203
47 Kosinski C, Mull M, Lethen H, Töpper R. Evidence for cardioembolic stroke in a case of Kearns-Sayre syndrome. Stroke 1995; 26 (10) 1950-1952
48 Furuya H, Sugimura T, Yamada T, Hayashi K, Kobayashi T. [A case of incomplete Kearns-Sayre syndrome with a stroke like episode]. Rinsho Shinkeigaku 1997; 37 (8) 680-684
49 Niehusmann P, Surges R, von Wrede RD , et al. Mitochondrial dysfunction due to Leber's hereditary optic neuropathy as a cause of visual loss during assessment for epilepsy surgery. Epilepsy Behav 2011; 20 (1) 38-43
50 Grazina MM, Diogo LM, Garcia PC , et al. Atypical presentation of Leber's hereditary optic neuropathy associated to mtDNA 11778G>A point mutation—A case report. Eur J Paediatr Neurol 2007; 11 (2) 115-118
51 Mazzaccara C, Iafusco D, Liguori R , et al. Mitochondrial diabetes in children: seek and you will find it. PLoS ONE 2012; 7 (4) e34956
52 Delmiro A, Rivera H, García-Silva MT , et al. Whole-exome sequencing identifies a variant of the mitochondrial MT-ND1 gene associated with epileptic encephalopathy: west syndrome evolving to Lennox-Gastaut syndrome. Hum Mutat 2013; 34 (12) 1623-1627
53 Elia M, Musumeci SA, Ferri R , et al. Leigh syndrome and partial deficit of cytochrome c oxidase associated with epilepsia partialis continua. Brain Dev 1996; 18 (3) 207-211
54 Yang PF, Jia YZ, Lin Q , et al. Intractable occipital lobe epilepsy: clinical characteristics, surgical treatment, and a systematic review of the literature. Acta Neurochir (Wien) 2015; 157 (1) 63-75
55 Adcock JE, Panayiotopoulos CP. Occipital lobe seizures and epilepsies. J Clin Neurophysiol 2012; 29 (5) 397-407
56 Hallmann K, Zsurka G, Moskau-Hartmann S , et al. A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy. Neurology 2014; 83 (23) 2183-2187
57 Girard JM, Turnbull J, Ramachandran N, Minassian BA. Progressive myoclonus epilepsy. Handb Clin Neurol 2013; 113: 1731-1736
58 Castro-Gago M, Blanco-Barca MO, Gómez-Lado C, Eirís-Puñal J, Campos-González Y, Arenas-Barbero J. Respiratory chain complex I deficiency in an infant with Ohtahara syndrome. Brain Dev 2009; 31 (4) 322-325
59 Tsuji M, Kuroki S, Maeda H , et al. Leigh syndrome associated with West syndrome. Brain Dev 2003; 25 (4) 245-250
60 Kang HC, Kim HD, Lee YM, Han SH. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr Neurol 2006; 35 (2) 158-161
61 Fujimoto S, Mizuno K, Shibata H , et al. Serial electroencephalographic findings in patients with MELAS. Pediatr Neurol 1999; 20 (1) 43-48
62 Nesbitt V, Alston CL, Blakely EL , et al. A national perspective on prenatal testing for mitochondrial disease. Eur J Hum Genet 2014; 22 (11) 1255-1259
63 Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM, Bindoff LA. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain 1995; 118 (Pt 2) 339-357
64 Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 2013; 81 (21) 1819-1826
65 Suomalainen A, Elo JM, Pietiläinen KH , et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011; 10 (9) 806-818
66 Research WTCfM. Stroke-like episodes in adult mitochondrial disease: investigation and management. Available at: http://www.newcastle-mitochondria.com/wp-content/uploads/2012/09/Stroke-Like-Episodes-Guidelines.pdf2013 . Accessed January 27, 2015
67 Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4: CD004426
68 Finsterer J, Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 2012; 8 (1) 71-79
69 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt 10) 2802-2818
70 Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011; 258 (2) 218-222
71 Howard RS, Russell S, Losseff N , et al. Management of mitochondrial disease on an intensive care unit. QJM 1995; 88 (3) 197-207
72 Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012; 135 (Pt 8) 2314-2328
73 Martikainen MH, Päivärinta M, Jääskeläinen S, Majamaa K. Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. Epileptic Disord 2012; 14 (4) 438-441
74 Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48 (1) 82-88
75 Joshi CN, Greenberg CR, Mhanni AA, Salman MS. Ketogenic diet in Alpers-Huttenlocher syndrome. Pediatr Neurol 2009; 40 (4) 314-316
76 Matthews Friends: ketogenic dietary therapies. Available at: www.matthewsfriends.org/ . Accessed November 20, 2014
77 Arthur TM, Saneto RP, de Menezes MS , et al. Vagus nerve stimulation in children with mitochondrial electron transport chain deficiencies. Mitochondrion 2007; 7 (4) 279-283
78 Carter BS. Comment to the paper: Palliative functional hemispherectomy for treatment of refractory status epilepticus associated with Alper's disease. Childs Nerv Syst 2011; 27 (8) 1325-1326
79 Duchowny M. Comment to the paper: palliative functional hemispherectomy for treatment of refractory status epilepticus associated with Alpers' disease. Childs Nerv Syst 2011; 27 (8) 1327-1328
80 Billings JA. The end-of-life family meeting in intensive care part I: indications, outcomes, and family needs. J Palliat Med 2011; 14 (9) 1042-1050
81 Billings JA, Block SD. The end-of-life family meeting in intensive care part III: a guide for structured discussions. J Palliat Med 2011; 14 (9) 1058-1064
82 Richardson J, Irving L, Hyslop LA , et al. Concise reviews: assisted reproductive technologies to prevent transmission of mitochondrial DNA disease. Stem Cells 2015; 33 (3) 639-645
83 Pfeffer G, Horvath R, Klopstock T , et al. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 2013; 9 (8) 474-481